Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study.

Autor: Françoise Laroche, Serge Perrot, Terkia Medkour, Paul-Henri Cottu, Jean-Yves Pierga, Jean-Pierre Lotz, Karine Beerblock, Christophe Tournigand, Laure Chauvenet, Didier Bouhassira, Joël Coste

Publikováno v: PLoS ONE, Vol 12, Iss 11, p e0187165 (2017)

Women with hormone-dependent breast cancer are treated with aromatase inhibitors (AI) to slow disease progression by decreasing estrogen levels. However, AI have adverse effects, including pain, with potentially serious impact on quality of life (QOL

Externí odkaz: https://doaj.org/article/a108ec18f141430386c35cf1c3b94dcb

Prognostic Factor Analysis in Advanced Gastric Cancer Patients Treated with Hydroxyurea, Leucovorin, 5-Fluorouracil, and Cisplatin (HLFP Regimen)

Autor: Thierry André, Christophe Louvet, Jean-Christophe Vaillant, Erick Gamelin, Aimery de Gramont, Frédéric Mal, May Mabro, Fabien Carrat, Jean Cady, Karine Beerblock

Publikováno v: Cancer Investigation. 21:14-20

This study was performed to determine the prognostic factors of 102 nonresectable locally advanced or metastatic gastric cancer patients prospectively treated with a multimodulation of 5-fluorouracil (5FU), hydroxyurea, leucovorin, and cisplatin. Res

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f059f8758203acc7681ac1aa8713a7c0
https://doi.org/10.1081/cnv-120016399

Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma

Autor: Thierry André, Elisabeth Carola, Karine Beerblock, Christophe Louvet, Roger Favre, Yves Rinaldi, Eric Raymond, Aimery de Gramont, Christophe Tournigand, Marcel Krulik

Publikováno v: Cancer. 79:1100-1105

BACKGROUND It has been suggested that there is a relationship between 5-fluorouracil (5-FU) dose levels and response rates. A bimonthly 2-day regimen of leucovorin (LV) and 5-FU bolus plus infusion has been found to be superior to a monthly 5-FU bolu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d2a5b12e88d61969ea08d4b0b8caece
https://doi.org/10.1002/(sici)1097-0142(19970315)79:6<1100::aid-cncr7>3.0.co

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients

Autor: François Lokiec, Jean-François Bernaudin, Pierre Saintigny, S. Hugonin, D. Avenin, Eric Levy, Pierre Levy, Karine Beerblock, Joseph Gligorov, Anne Fajac, Frédéric Selle, Keyvan Rezai

Publikováno v: British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2010, 103 (4), pp.560-6. ⟨10.1038/sj.bjc.6605789⟩
British Journal of Cancer, 2010, 103 (4), pp.560-6. ⟨10.1038/sj.bjc.6605789⟩

International audience; BACKGROUND: It can be hypothesised that inherited polymorphisms in the drug-transporter ABCB1 gene may interfere with interindividual variations in drug response in breast cancer patients. Docetaxel is a substrate for ABCB1 wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23bb301379cb88c155becc23b6309a4
https://hal.sorbonne-universite.fr/hal-00597585

Aromatase inhibitor pain syndromes: Classification and determination of specific risk factors—A prospective multicenter cohort study

Autor: Christophe Tournigand, Paul Cottu, Jean-Pierre Lotz, Karine Beerblock, Serge Perrot, F Borderie, Laure Chauvenet, T. Medkour, Joël Coste, Frédéric Batteux, Jean-Yves Pierga, D Boussahira, Xavier Declèves, Françoise Laroche

Publikováno v: ResearcherID

569 Background: Pain is frequent during Aromatase Inhibitors (AIs) treatment for breast cancer and several pain syndromes have been reported but not precisely defined. We developed a prospective multicentre study aiming at classifying AIs-related pai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97f0c047db660331702db789de56619
https://doi.org/10.1200/jco.2013.31.15_suppl.569